Trending menu:
Comment
-
17 January 2020
Biogen’s aducanumab leans toward conditional versus full approval in Alzheimer’s
Biogen’s aducanumab is more likely to be granted conditional versus full FDA approval in Alzheimer’s disease (AD) based on recently presented data. The results presented in the Phase III EMERGE...
-
9 January 2020
Gene silencing therapy’s fast-track approval to expand treatment options for Huntington’s patients
Globally, there are currently 24 products in clinical development for the treatment of Huntington’s disease, which is a rare, inheritable neurodegenerative condition. Symptoms are typically noticed between the ages of...
-
7 January 2020
Experts sceptical on Bristol-Myers Squibb’s head and neck cancer trial of Opdivo
Bristol-Myers Squibb’s Phase III first-line head and neck squamous cell carcinoma (HNSCC) trial of Opdivo (nivolumab) and Yervoy (ipilimumab) has several experts pessimistic on trial success while others said a...
-
7 January 2020
UniQure’s etranacogene dezaparvovec in haemophilia B has experts positive on Phase III prospects
UniQure’s AMT-061 (etranacogene dezaparvovec) in haemophilia B is expected to achieve clinically significant results in its Phase III HOPE-B trial, despite divided expert opinion about the company’s decision to enrol...
-
3 January 2020
iRhythm to participate in atrial fibrillation study to reduce stroke rates
In December 2019, iRhythm announced that it is participating in the Guard-AF study by Bristol-Myers Squibb–Pfizer. The study aims to determine if earlier detection of atrial fibrillation (AFib) in undiagnosed...
-
2 January 2020
BeiGene’s Phase III Trial of Zanubrutinib Misses Late-Stage Goals in Waldenström’s Macroglobulinemia
Beigene announced that its Phase III Trial of zanubrutinib compared to Johnson & Johnson/AbbVie’s ibrutinib did not achieve statistical significance for its primary endpoint. While zanubrutinib failed to achieve superiority...
-
2 January 2020
Report raises doubts about influential clinical trial and heart disease guidelines
On December 9th, BBC Newsnight came out with an investigation questioning the validity of the 2016 EXCEL clinical trial, led by Dr Gregg Stone, published in the New England Journal...
-
23 December 2019
Overview of industry-sponsored clinical trials in the UK, 2019
Novartis is the top sponsor, holding 4.9% of clinical trials, narrowly outnumbering AstraZeneca, which sponsored 4.6% of trials.
-
23 December 2019
Novartis discontinues asthma drug candidate fevipiprant following another Phase III trial failure
Shares in Gossamer Bio, which has a lead drug candidate with a similar mechanism of action to fevipiprant, fell following Novartis’ recent announcement.
-
23 December 2019
UCB’s bimekizumab outperforms AbbVie’s Humira in psoriasis patients
The BE SURE study is one of six ongoing clinical trials of bimekizumab in psoriasis and is UCB’s third study that has shown positive results this year.